KKR to take Integer private in US$5.7bn deal
KKR will take Integer Holdings private in an all-cash US$5.7bn deal, paying US$127 per share plus assuming Integer’s outstanding debt. The offer is a 4.78% premium. Integer makes components for medical devices in cardiovascular and neuromodulation. KKR said the deal should close by year-end, expanding its healthcare exposure.
How this was made
The 30-second read
Why it matters
The all-cash offer at a stated premium creates an immediate valuation anchor for ITGR and a deal-risk trading framework for both ITGR and KKR until closing.
Market read
This is a primary M&A disclosure with concrete economics (offer price, premium, deal size) and a defined closing window, making it tradable via deal-spread and execution-risk positioning.
What to watch
The article notes activist history and board changes; traders should monitor whether governance disputes or debt terms create execution risk before year-end closing.
Background
KKR is expanding its healthcare portfolio via a take-private of Integer Holdings, a medical device components and finished products supplier.
Ticker impact
KKR agreed to take Integer Holdings private in an all-cash US$5.7bn deal, expanding its healthcare exposure and assuming Integer debt.
Likely modest positive bias for KKR on deal headlines, with volatility around regulatory/closing updates.
The article discloses deal size, price per share, premium, and expected close timing, which are actionable for M&A risk/reward positioning.
Integer Holdings will be taken private by KKR in an all-cash US$5.7bn transaction at US$127 per share, including assumption of its outstanding debt.
Supportive for ITGR toward offer value, but expect spread compression/expansion as deal certainty headlines emerge.
The article provides the offer price, premium to the prior close, all-cash structure, debt assumption, and an end-of-year closing expectation.
Market effects
Medtech M&A read-through may improve sentiment for device suppliers as PE signals value realization in public medtech.
US medtech deal activity narrative could marginally influence sentiment for other US-listed device makers.
Cross-border investors may view the transaction as a signal for continued global PE appetite in healthcare assets.
Counterpoint
Even with a premium, deal spreads can widen if activist pressure, financing conditions, or regulatory scrutiny increases closing risk.
Key entities
- acquirerKKR
Announced an all-cash US$5.7bn take-private of Integer to expand healthcare exposure.
- targetInteger Holdings
Agreed to be taken private at US$127 per share, with KKR assuming outstanding debt.
- activist/major shareholderIrenic Capital Management
Agreed in March to appoint two directors; owns more than 3% stake per LSEG data.
